Just weeks before Fresenius was allowed by a federal judge to walk away from its buyout of Akorn over quality concerns, FDA inspectors were in Akorn’s New Jersey plant for another inspection. What they found in the sterile drug facility were issues similar to those that led the German company to abandon the $4.3 billion deal.
